Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

Gefitinib and erlotinib, which are epidermal growth factor receptor- (EGFR-) specific tyrosine kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is becoming essential for the treatment of NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosaka, Takayuki, Yamaki, Ei, Mogi, Akira, Kuwano, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114474/
https://www.ncbi.nlm.nih.gov/pubmed/21687596
http://dx.doi.org/10.1155/2011/165214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114474/
https://www.ncbi.nlm.nih.gov/pubmed/21687596
http://dx.doi.org/10.1155/2011/165214

Ejemplares similares